Try our beta test site

A Study to Measure Needle Bending and Changes in Prostate Shape During a Prostate Seed Implant

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01437085
First received: September 19, 2011
Last updated: January 23, 2017
Last verified: January 2017

September 19, 2011
January 23, 2017
October 2011
August 2017   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01437085 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Measure Needle Bending and Changes in Prostate Shape During a Prostate Seed Implant
Quantifying Needle Deflection and Tissue Deformation in Transperineal Interstitial Permanent Prostate Brachytherapy: A Basis for Development of Next-Generation Implant Technique
Prostate brachytherapy is an effective treatment option for men with localized prostate cancer, with excellent cure rates and a favorable toxicity profile. With the current needle insertion technique, seed placement inaccuracy is primarily caused by needle deflection and soft tissue deformation, which both occur during the brachytherapy operation. This study will accrue 20 patients undergoing prostate brachytherapy implants and acquire a series of ultrasound images, video clips and one CT scan.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients having a prostate brachytherapy implant at the Cross Cancer Institute.
Prostate Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
25
August 2017
August 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prostate cancer
  • Treated with prostate brachytherapy at the Cross Cancer Institute
  • Low and intermediate risk prostate cancer
  • ambulatory patients
  • stable medical condition
  • Over 18 years of age
  • Capable of giving informed consent

Exclusion Criteria:

  • Any hormonal therapy
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01437085
25837
No
Not Provided
Not Provided
Not Provided
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Not Provided
Principal Investigator: Nawaid Usmani, MD, FRCPC University of Alberta
AHS Cancer Control Alberta
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP